Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
21801
Takaki EO, Kiyono K, Obuchi Y, Yamauchi T, Watanabe T, Matsumoto H, Karimine M, Kuniyoshi Y, Nishikori S, Yokoyama F, Nishimori H, Nabeshima H, Nakamura K.
A PDE3A-SLFN12 Molecular Glue Exhibits Significant Antitumor Activity in TKI-Resistant Gastrointestinal Stromal Tumors.Clin Cancer Res
2024
PubMed ID: 38864850
DOI: 10.1158/1078-0432.CCR-24-0096
20137
Ito Y, Terao Y, Noma S, Tagami M, Yoshida E, Hayashizaki Y, Itoh M, Kawaji H.
Nanopore sequencing reveals TACC2 locus complexity and diversity of isoforms transcribed from an intronic promoter.Sci Rep
2021
11(1):9355
PubMed ID: 33931666
DOI: 10.1038/s41598-021-88018-9
12164
Mary Ellen Urick, Daphne W. Bell
Proteomic profiling of FBXW7‐mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic targetORIGINAL RESEARCH
2020
PubMed ID: 32248654
DOI: 10.1002/cam4.3013
8772
Sugimoto T, Koizumi T, Sudo T, Yamaguchi S, Kojima A, Kumagai S, Nishimura R.
Correlative expression of cyclooxygenase-1 (Cox-1) and human epidermal growth factor receptor type-2 (Her-2) in endometrial cancer.Kobe J Med Sci
2007
53:177-87
PubMed ID: 18204294